Section of General Internal Medicine, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA.
Clin Cardiol. 2010 Nov;33(11):666-71. doi: 10.1002/clc.20822.
Hyponatremia is common and is increasingly recognized as an independent prognostic marker that adversely affects morbidity and mortality in various disease states, including heart failure. In acute decompensated heart failure (ADHF), the degree of hyponatremia often parallels the severity of cardiac dysfunction and is further exacerbated by any reduction in glomerular filtration rate and arginine vasopressin dysregulation. A recent study showed that even modest improvement of hyponatremia may have survival benefits. Although management of hyponatremia in ADHF has traditionally focused on improving cardiac function and fluid restriction, the magnitude of improvement of serum sodium is fairly slow and unpredictable. In this article, we discuss the mechanisms of hyponatremia in ADHF, review its evolving prognostic significance, and evaluate the efficacy of various treatments for hyponatremia, including the recently approved vasopressin receptor antagonists for managing hyponatremia among patients hospitalized for ADHF.
低钠血症很常见,并且越来越被认为是一种独立的预后标志物,会对各种疾病状态(包括心力衰竭)的发病率和死亡率产生不利影响。在急性失代偿性心力衰竭(ADHF)中,低钠血症的严重程度通常与心功能障碍的严重程度平行,并因肾小球滤过率降低和精氨酸加压素失调而进一步加重。最近的一项研究表明,即使低钠血症略有改善也可能有生存获益。尽管 ADHF 中的低钠血症管理传统上侧重于改善心功能和限制液体摄入,但血清钠的改善幅度相当缓慢且不可预测。在本文中,我们讨论了 ADHF 中低钠血症的机制,回顾了其不断发展的预后意义,并评估了各种低钠血症治疗方法的疗效,包括最近批准的血管加压素受体拮抗剂,用于治疗因 ADHF 住院的患者的低钠血症。